EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

Yalan Zhou, Siqi Peng, Huizhen Wang, Xinyin Cai, Qingzhong Wang iD

Genes · 08.04.2024 · 15 (4) · 468

DOI: 10.3390/genes15040468 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 08.04.2024. Verfasst von Yalan Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Hauptthemen laut MEDLINE: Precision Medicine, Biological Products, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, the FDA has approved numerous anti-cancer drugs that are mutation-based for clinical use. These drugs have improved the precision of treatment and reduced adverse effects and side effects. Personalized therapy is a prominent and hot topic of current medicine and also represents the future direction of development. With the continuous advancements in gene sequencing and high-throughput screening, research and development strategies for personalized clinical drugs have developed rapidly. This review elaborates the recent personalized treatment strategies, which include artificial intelligence, multi-omics analysis, chemical proteomics, and computation-aided drug design. These technologies rely on the molecular classification of diseases, the global signaling network within organisms, and new models for all targets, which significantly support the development of personalized medicine. Meanwhile, we summarize chemical drugs, such as lorlatinib, osimertinib, and other natural products, that deliver personalized therapeutic effects based on genetic mutations. This review also highlights potential challenges in interpreting genetic mutations and combining drugs, while providing new ideas for the development of personalized medicine and pharmacogenomics in cancer study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineBiological ProductsNeoplasmsAntineoplastic AgentsPharmacogeneticsHumansMutation

Stichwörter der Autor:innen

anticancernatural productspersonalized medicinepersonalized therapypharmacogenomics

Substanzen

Biological ProductsAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • Shanghai R&D Centre for Standardization of Chinese Medicines, Shanghai 202103, China.

ORCID-Profile: Qingzhong Wang

Förderung

  • National Natural Science Foundation of China
  • Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine
  • Shanghai Municipal Health Commission

Zitieren

APA

Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024). Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes, 15(4), 468. https://doi.org/10.3390/genes15040468

Vancouver

Zhou Y, Peng S, Wang H, Cai X, Wang Q. Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products. Genes. 2024;15(4):468. doi:10.3390/genes15040468

BibTeX
@article{Zhou2024,
  author = {Zhou, Yalan and Peng, Siqi and Wang, Huizhen and Cai, Xinyin and Wang, Qingzhong},
  title = {Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products},
  journal = {Genes},
  year = {2024},
  volume = {15},
  number = {4},
  pages = {468},
  doi = {10.3390/genes15040468}
}
Kostenlos starten →